On May 28, 2023, the Board of Directors of Rain Oncology Inc. approved a restructuring plan in connection with a reprioritization of the Company's clinical strategy designed to optimize Company resources. As previously announced, the Company intends to suspend enrollment in its Phase 2 MANTRA-2 basket trial and terminate plans to initiate its Phase 1/2 MANTRA-4 combination trial. The Company expects to continue to evaluate outcomes from its MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma, with data and findings expected to be presented at a medical conference in the fourth quarter of fiscal 2023.
1st Jan change | Capi. | |
---|---|---|
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |